Manhattan Associates, Inc. (MANH) Forms $52.26 Double Bottom; 10 Analysts Bullish Laboratory of America Holdings (LH)

Manhattan Associates, Inc. (MANH) formed double bottom with $48.08 target or 8.00% below today’s $52.26 share price. Manhattan Associates, Inc. (MANH) has $3.60B valuation. The stock increased 1.83% or $0.94 during the last trading session, reaching $52.26. About 602,515 shares traded. Manhattan Associates, Inc. (NASDAQ:MANH) has declined 22.39% since January 9, 2017 and is downtrending. It has underperformed by 39.09% the S&P500.

Among 19 analysts covering Laboratory Corp (NYSE:LH), 10 have Buy rating, 0 Sell and 9 Hold. Therefore 53% are positive. Laboratory Corp had 48 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, July 27 by Craig Hallum. The stock of Laboratory Corporation of America Holdings (NYSE:LH) has “Buy” rating given on Monday, October 16 by Piper Jaffray. The stock of Laboratory Corporation of America Holdings (NYSE:LH) has “Neutral” rating given on Monday, February 6 by Robert W. Baird. Barclays Capital maintained Laboratory Corporation of America Holdings (NYSE:LH) on Thursday, July 27 with “Overweight” rating. The company was maintained on Sunday, October 15 by Robert W. Baird. The stock of Laboratory Corporation of America Holdings (NYSE:LH) earned “Neutral” rating by Mizuho on Thursday, September 15. Wells Fargo upgraded Laboratory Corporation of America Holdings (NYSE:LH) rating on Thursday, October 12. Wells Fargo has “Buy” rating and $175.0 target. The rating was downgraded by KeyBanc Capital Markets to “Sector Weight” on Tuesday, June 27. The firm earned “Sector Perform” rating on Friday, February 19 by RBC Capital Markets. The firm has “Hold” rating given on Wednesday, July 12 by Credit Suisse. See Laboratory Corporation of America Holdings (NYSE:LH) latest ratings:

05/01/2018 Broker: Evercore Rating: Outperform New Target: $176 Initiates Coverage On
03/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $190.0 Maintain
11/12/2017 Broker: Credit Suisse Rating: Hold New Target: $170.0 Downgrade
01/12/2017 Broker: Mizuho Rating: Hold New Target: $165.0 Maintain
24/11/2017 Broker: Jefferies Rating: Hold New Target: $167.0 Maintain
26/10/2017 Broker: Craig Hallum Rating: Buy New Target: $180.0 Maintain
26/10/2017 Broker: Barclays Capital Rating: Overweight Old Target: $183 New Target: $190 Maintain
26/10/2017 Broker: Deutsche Bank Rating: Buy Old Target: $170 New Target: $172 Maintain
19/10/2017 Broker: Jefferies Rating: Hold New Target: $170.0 Maintain
17/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $175.0 Maintain

Among 7 analysts covering Manhattan Assoc (NASDAQ:MANH), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Manhattan Assoc has $80 highest and $45 lowest target. $69.40’s average target is 32.80% above currents $52.26 stock price. Manhattan Assoc had 13 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was initiated by Brean Capital with “Buy” on Tuesday, January 12. As per Tuesday, October 3, the company rating was upgraded by SunTrust. The rating was initiated by Lake Street with “Buy” on Monday, October 19. On Thursday, April 28 the stock rating was downgraded by William Blair to “Market Perform”. Benchmark maintained the shares of MANH in report on Wednesday, July 22 with “Buy” rating. The firm has “Mkt Perform” rating given on Monday, January 9 by Raymond James. KeyBanc Capital Markets maintained Manhattan Associates, Inc. (NASDAQ:MANH) on Wednesday, August 23 with “Hold” rating. William Blair initiated the stock with “Outperform” rating in Tuesday, September 29 report. The firm has “Buy” rating given on Wednesday, November 15 by SunTrust. The firm earned “Buy” rating on Wednesday, October 21 by Benchmark.

Investors sentiment increased to 1.33 in 2017 Q3. Its up 0.26, from 1.07 in 2017Q2. It is positive, as 35 investors sold Manhattan Associates, Inc. shares while 67 reduced holdings. 35 funds opened positions while 101 raised stakes. 72.05 million shares or 1.48% less from 73.13 million shares in 2017Q2 were reported. Price T Rowe Inc Md reported 728,321 shares. Moreover, American Century Cos Incorporated has 0% invested in Manhattan Associates, Inc. (NASDAQ:MANH) for 11,189 shares. Disciplined Growth Inc Mn holds 0.81% or 925,100 shares. Virtu Ltd Liability Corp stated it has 10,290 shares. Tower Capital Ltd Company (Trc) invested 0% in Manhattan Associates, Inc. (NASDAQ:MANH). Schwab Charles Inv Mngmt accumulated 0.01% or 362,661 shares. Great Lakes Advsr Llc holds 98,129 shares. Lloyds Banking Gru Public Ltd Company accumulated 3,747 shares. Credit Suisse Ag has invested 0% in Manhattan Associates, Inc. (NASDAQ:MANH). Blair William & Il has invested 0% of its portfolio in Manhattan Associates, Inc. (NASDAQ:MANH). Next Financial Grp Incorporated Inc holds 0.01% in Manhattan Associates, Inc. (NASDAQ:MANH) or 425 shares. Oregon Public Employees Retirement Fund has invested 0.02% of its portfolio in Manhattan Associates, Inc. (NASDAQ:MANH). Ls Limited Liability Corp holds 5,252 shares. Convergence Prtnrs Ltd has invested 0.22% of its portfolio in Manhattan Associates, Inc. (NASDAQ:MANH). Moreover, Vident Invest Advisory Limited Liability has 0.65% invested in Manhattan Associates, Inc. (NASDAQ:MANH).

Analysts await Manhattan Associates, Inc. (NASDAQ:MANH) to report earnings on January, 30. They expect $0.42 EPS, 0.00% or $0.00 from last year’s $0.42 per share. MANH’s profit will be $28.95 million for 31.11 P/E if the $0.42 EPS becomes a reality. After $0.48 actual EPS reported by Manhattan Associates, Inc. for the previous quarter, Wall Street now forecasts -12.50% negative EPS growth.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory firm worldwide. The company has market cap of $16.89 billion. It operates through two divisions, LabCorp Diagnostics and Covance Drug Development. It has a 23.14 P/E ratio. The firm offers a range of clinical laboratory tests and procedures, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, tests for sexually-transmitted diseases, HCV tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens.

The stock decreased 0.32% or $0.54 during the last trading session, reaching $165.94. About 749,156 shares traded or 20.34% up from the average. Laboratory Corporation of America Holdings (NYSE:LH) has risen 10.51% since January 9, 2017 and is uptrending. It has underperformed by 6.19% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: